Quince Therapeutics, Inc. current ratio

The Current Ratio as of October 2026 (TTM) for Quince Therapeutics, Inc. (QNCX) is 14.52

According to Quince Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 14.52. This represents a change of 204.26% compared to the average of 4.77 of the last 4 quarters.

Quince Therapeutics, Inc. (QNCX) Historical Current Ratio (quarterly & annually)

How has QNCX Current Ratio performed in the past?

The mean historical Current Ratio of Quince Therapeutics, Inc. over the last ten years is 14.13. The current 14.52 Current Ratio has changed 2.73% with respect to the historical average. Over the past ten years (40 quarters), QNCX's Current Ratio was at its highest in in the December 2018 quarter at 49.82. The Current Ratio was at its lowest in in the March 2018 quarter at 0.

Quince Therapeutics, Inc. (QNCX) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Quince Therapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Quince Therapeutics, Inc. (QNCX) Average Current Ratio

How has QNCX Current Ratio performed in the past?

The current Current Ratio of Quince Therapeutics, Inc. (QNCX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Quince Therapeutics, Inc. (QNCX) Current Ratio vs. Peers

How is QNCX’s Current Ratio compared to its peers?

Quince Therapeutics, Inc.’s Current Ratio is greater than aTyr Pharma, Inc. (5.12), greater than Precision BioSciences, Inc. (10.47), greater than InflaRx N.V. (7.26), greater than Metagenomi, Inc. Common Stock (4.50), greater than Fractyl Health, Inc. (3.15), greater than ALX Oncology Holdings Inc. (9.71), greater than Connect Biopharma Holdings Limited (2.37), greater than Adverum Biotechnologies, Inc. (0.65), greater than CAMP4 Therapeutics Corporation (4.70), greater than Kalaris Therapeutics Inc (10.98),

Build a custom stock screener for Quince Therapeutics, Inc. (QNCX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Quince Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Quince Therapeutics, Inc. (QNCX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Quince Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.